CHICAGO – With yet another new generation of ALK inhibitors nearing market entrance for non-small cell lung cancer, experts are considering where the current generation of ALK targeted therapies, ...
Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trial TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA ...
Maruti Suzuki offers discounts up to Rs 2.15 lakh on premium Nexa series models in April Hyundai provides maximum discounts of Rs 60,000 on Alkazar and Grand i10 Nios models Tata Motors PV announces ...
Cooper & Gorfer, “Segal and The Tiger.” Courtesy of 212 Photography Istanbul. Tugberk Acar, “Tamer Yılmaz and Azra Akin,” in which the photo artist Tamer Yilmaz (right) joins his subject. Courtesy of ...
Last Friday, a Facebook user posted the former Alkazar Hotel in the public group "Gold Trails & Ghost Towns." The hotel, which was in operation from 1906 to 1910, was once situated at Highway 3 and ...
Około 150 duchownych katolickich wzięło udział w Powstaniu Warszawskim jako kapelani poszczególnych oddziałów i szpitali polowych. W ciągu 63 dni wolnościowego zrywu byli stale przy walczących – ...
Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy. On July 21, Nuvalent announced that the first patient had been dosed in ALKAZAR, which is its global Phase 3 randomized, ...
VCU Massey is the first U.S. site in a global phase 2a trial for PTX-100, targeting cutaneous T-cell lymphoma. The BIPAVE-001 trial is evaluating AI-081, a PD-1 and VEGF bispecific antibody, for ...
Nuvalent ( (NUVL)) has issued an update. On July 21, 2025, Nuvalent, Inc. announced the initiation of its Phase 3 clinical trial, ALKAZAR, to evaluate neladalkib for TKI-naïve patients with advanced ...
NEW YORK – Nuvalent said on Monday it has started treating patients in a Phase III trial of its fourth-generation ALK inhibitor neladalkib for patients with advanced ALK-positive non-small cell lung ...
The ALKAZAR trial is designed to enroll approximately 450 TKI-naïve patients with advanced ALK-positive NSCLC. Patients will be randomized 1:1 to receive neladalkib monotherapy or alectinib ...
CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (NUVL) (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results